A Review of a Recent Meta-Analysis Study on Obstructive Sleep Apnea

Article information

J Rhinol. 2022;29(3):134-140

Publication date (electronic) : 2022 November 30

doi : https://doi.org/10.18787/jr.2022.00422

Bo Yoon Choi, MD

, Jin Kook Kim, MD, PhD

, Jae Hoon Cho, MD, PhD, MPH

Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine Konkuk University, Seoul, Republic of Korea

Address for correspondence: Jae Hoon Cho, MD, PhD, MPH, Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine Konkuk University, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Republic of Korea Tel: +82-2-2030-7667, Fax: +82-2-2030-5299, E-mail: jaehoon@kuh.ac.kr

Received 2022 October 1; Revised 2022 November 22; Accepted 2022 November 23.

Abstract

This paper summarizes a recent meta-analysis of various topics in obstructive sleep apnea (OSA). In addition to cardiovascular disease and neurocognitive dysfunction, a wide variety of diseases have been associated with OSA, and associations with cancer have also been reported. Although continuous positive airway pressure is a very effective treatment, the results have shown that it does not reduce the incidence of various complications. It has been reported that uvulopalatopharyngoplasty was effective, and robotic surgery for the tongue root and hypoglossal nerve stimulation were also effective. The effectiveness of various medications to reduce daytime sleepiness has also been demonstrated. Although exercise lowered the apnea-hypopnea index, it was not related to changes in body composition, and it was also reported that exercise combined with weight control were effective. Additionally, interesting and clinically meaningful meta-analysis results were summarized and presented.

Keywords: Obstructive sleep apnea; Meta-analysis

INTRODUCTION

Obstructive sleep apnea (OSA) is a disease involving repeated narrowing of the upper respiratory tract during sleep, which causes a decline or discontinuation of respiratory airflow. It is characterized by frequent sleep fragmentation and hypoxia [1]. The incidence rate of OSA is very high, as nearly a billion patients are estimated to exist across the world [2]. Symptoms include severe daytime sleepiness, headache, fatigue, and loss of concentration [3]. It also increases the possibility of hypertension [4], diabetes [5], stroke [6], arrhythmia [7], and other complications as well as car accidents and workplace accidents, which may ultimately result in death. Continuous positive airway pressure (CPAP) is highly effective against OSA. However, due to low compliance, other treatments are often used including surgery and oral appliances.

Meta-analysis is a statistical method of collecting, reviewing, and compiling previously published literature to draw certain conclusions [8]. Meta-analysis is widely used for discussing interesting and controversial topics in the relevant field. As such, the method allows researchers to easily track the key research trends and outcomes in the field, and infer the best results for topics that have not been concluded clearly so far. The purpose of this meta-analysis is to cover various topics related to OSA and provide readers with the latest knowledge and opinions in the field of OSA studies.

LITERATURE SEARCH METHOD

We searched for all meta-analysis studies published on OSA between January 1, 2017 and February 18, 2022, the day when we carried out the search. We searched the studies at PubMed with the search word ‘obstructive sleep apnea,’ using the filter function to narrow down the article types to ‘meta-analysis.’ The search found 384 articles. We reviewed each of them to select interesting studies with high clinical value, and grouped the selected articles across different topics (Fig. 1).

Fig. 1.

Flowchart of study selection. OSA, obstructive sleep apnea; CPAP, continuous positive airway pressure.

COMPLICATIONS ASSOCIATED WITH OSA

Although exact mechanisms have not been identified, OSA is known to cause or exacerbate various complications. Recent meta-analysis studies have affirmed this association. The most well-known complications include: hypertension, coronary artery diseases and other cardiovascular diseases [6,9-15], the Parkinson’s diseases, anxiety disorders, depression, and other neurological-cognitive disorders [16-20]. Many studies have repeatedly presented consistent findings regarding these complications, and their level of association with OSA is quite high. Studies have also suggested association with lesser-known complications [21-28] including rheumatoid arthritis [29], interstitial lung disease [30], central serous chorioretinopathy [31], and hypermobility syndrome [32] (Table 1). In addition, for some of these complications, metaanalysis articles have reached opposing conclusions about their association with OSA, and researchers continue to report a wide range of other diseases associated with OSA.

Table 1.

Various complications related with obstructive sleep apnea

OSA AND CANCER

In recent years, researchers have continuously reported associations between OSA and cancer. A meta-analysis on twelve articles (total no. of patients: 862,820) reported that the cancer rate of OSA patients was 0.046% higher than the control group (95% confidence interval [CI]: 0.027–0.065), without clear associations with specific cancers [33]. As for specific cancer types, many studies have reported the association between OSA and melanoma. A meta-analysis study analyzed six of these articles involving 5,276,451 patients, and found that the melanoma risk ratio of OSA patients was 1.71 times higher than the control group (95% CI: 1.08–2.69) [34].

LIMITATIONS OF CPAP

CPAP is one of the most effective treatments for OSA. As such, various studies were conducted on CPAP under the expectation that it will reduce various complications associated with OSA. Of note, as many studies reported that CPAP decreases the blood pressure of OSA patients with hypertension [35], it was logically believed that it can reduce cardiovascular complications as well. A meta-analysis study involving eight randomized controlled trials was designed to test this possibility. This analysis, which involved 5,817 subjects, analyzed the relative risk of cardiovascular diseases in patients treated with CPAP. The overall risk of major cardiovascular diseases was 0.87 (95% CI: 0.70–1.10), and the relative risk of cardiovascular death was 0.94 (95% CI: 0.62–1.43), the relative risk of myocardial infarction was 1.04 (95% CI: 0.79–1.37), and the relative risk of angina was 1.05 (95% CI: 0.51–2.15). CPAP also did not have preventive effect on cardiovascular diseases including heart failure, stroke, and atrial fibrillation [36]. Another study conducted a similar meta-analysis on ten randomized controlled trials (7,266 patients), and the relative risk of acute coronary artery diseases, stroke, and vascular death was 0.77 (95% CI: 0.53–1.13), which suggests that CPAP did not reduce the risk of these diseases comparing with the control group. In sum, in both studies, CPAP did not have preventive effect on various cardiovascular diseases [37]. As both studies only covered randomized controlled trials, the effect of confounding variables during the selection of the CPAP group and the control group seems to be minimal. If we also consider the difference between the duration of CPAP use (4 hours or longer and less than 4 hours) did not produce meaningful differences in either study, it is credible that CPAP does not reduce the occurrence of cardiovascular complications.

Numerous studies have observed the effect of CPAP of type 2 diabetes, which is another main complication associated with OSA. A meta-analysis study involving six randomized controlled trials (581 patients) was performed. A comparison of HbA1c levels at 12 or 24 weeks after CPAP treatment showed mean difference of -0.10 (95% CI: -0.25–0.04), which is not significant. The result is same, even in patients who used CPAP for four hours or longer per day. In addition, the CPAP group and the control group showed similar fasting glucose levels [38].

Excessive abdominal visceral fat is also known as a complication of OSA. In a meta-analysis on five studies that analyzed changes in abdominal visceral fat after CPAP treatment (169 patients), no change in abdominal visceral fat was observed after CPAP treatment (standardized mean difference: 0.00, 95% CI: -0.21–0.21). The result is not different by the CPAP treatment duration, patients’ ages, or their body mass indexes [39].

As discussed above, many studies reported disappointing findings about the preventive effect of CPAP. However, positive findings have been reported as well. CPAP lowers blood pressure [35], and reduces various inflammatory substances [40], cortisol [41], and proteinuria [42]. It also reduces gastroesophageal reflux disease [43], and erectile dysfunction [44].

SURGICAL TREATMENTS OF OSA

There have been many studies that denies the effectiveness of the soft palate surgery as a treatment for OSA. However, there also have been many studies that support the effectiveness of the soft palate surgery [45-48]. A recent meta-analysis study of 59 soft palate surgeries included anterior and lateral palatopharyngoplasty as well as conventional uvulopalatopharyngoplasty, and compared the results before and after the surgeries. The apnea-hypopnea index (AHI) declined from 35.66 to 13.91 after the surgeries (p<0.001), and the Epworth Sleepiness Scale (ESS) also declined from 11.65 to 5.08 (p<0.001) [49].

Many studies reported findings on OSA surgeries using robots, which are mainly used to dissect the root of the tongue. A meta-analysis on 31 of these studies (1,693 patients) found a 24.3 decline in the AHI (95% CI: 21.69–26.81), a 7.92 decline in ESS (95% CI: 6.50–9.34), a 6.04% increase in the lowest oxygen saturation (95% CI: 3.05–9.03), and 69% in a surgery success rate (95% CI: 64–79). However, these findings provide low evidence for proving the effectiveness of the robot surgeries, because most of the robot surgeries were performed along with soft palate surgeries and the studies did not include any control group [50].

Recently one of the most notable surgical treatments for OSA is the hypoglossal nerve stimulation therapy. This therapy inserts an electrode in the human body to stimulate the hypoglossal nerves to resolve tongue root blocking. It has been recognized as effective in numerous studies and was approved by the United States Food and Drug Administration in 2014. Korea is also hurrying the approval process. A meta-analysis was conducted on 15 studies (808 patients) published on this topic, which found a 24.9 decline in the AHI (95% CI: 21.1– 28.5) [51].

Before the hypoglossal nerve stimulation therapy was developed, transcutaneous electrical stimulation has been attempted in some cases to stimulate the hypoglossal nerves. Conflicting findings have been reported regarding this method. In a meta-analysis on five studies (87 patients) on this method, the AHI decline by 16.5 (95% CI: 7.7–25.1) [51].

MEDICATIONS FOR OSA

In the past, modafinil was widely used for treating narcolepsy and hypersomnia associated with OSA, and a large number of studies were performed on the topic [52,53]. Since then, various medications have been developed for OSA. Solriamfetol is a norepinephrine–dopamine reuptake inhibitor developed by a Korean pharmaceutical company [54,55]. Five randomized controlled trials (1,777 patients) were conducted regarding esolriamfetol, and a meta-analysis on these studies found that solriamfetol lowered the ESS by an average of 3.74 points (95% CI: 3.09–4.38) [56]. Pitolisant (histamine 3 receptor antagonist/inverse agonist) is a new medication recently developed for OSA. Four randomized controlled trials (678 patients) were conducted regarding pitolisant, and a metaanalysis on these studies found a 2.86 decline in the ESS (95% CI: 1.96–3.75) and a 3.14-minutes increase in sleep latency (95% CI: 2.18–4.11) [57].

Non-benzodiazepine hypnotics, such as zolpidem, zaleplon, and eszopiclone, improve sleep onset and sleep continuity without changing the overall sleep stages [58,59]. As such, these drugs were expected to increase CPAP compliance of OSA patients. According to a meta-analysis on this issue, nonbenzodiazepine hypnotics increased the average time for CPAP use by 0.62 hour (95% CI: 0.26–0.98) and increased the days of CPAP use by 12.08% (95% CI: 5.27–18.88). Among them, eszopiclone proved to be the most effective [60].

Some studies found that serotonin leads to the contraction of the genioglossus and the upper airway dilating muscles by stimulating the hypoglossal nerves [61,62]. A meta-analysis on these studies concluded that serotonin is not recommended as an OSA treatment. Although some studies reported a decline in the AHI comparing with the control group, they did not have a sufficient sample size and have a high risk of bias. Also, serotonin itself is highly likely to cause adverse side effects [63].

EFFECT OF EXERCISE IN OSA TREATMENT

Exercise is emphasized as a key element in the treatment of OSA patients. It is widely known that exercise improves OSA by reducing weight of patients. Some studies have shown that changes in body composition plays a certain part as well; exercise lowers the patient’s body fat and increases the muscle mass, reducing the obstruction of the upper respiratory tract and finally reducing OSA. A meta-analysis on this topic found that OSA patients with exercise have a significant reduction in the body body mass index (-0.55 kg/m2, 95% CI: -0.95 to -0.15) and a significant decline in the AHI (-8.06/hour, 95% CI: -10.47 to -5.66). However, no significant change was observed in body fat. To summarize, while exercise lowers the AHI, it is not an effect from changes in body composition [64].

According to a meta-analysis on the effect of weight loss and lifestyle changes in OSA patients, the effect of diet control, exercise, sleep environment, and cessation of alcohol consumption and smoking had different effects depending on the specific method and the targets. However, weight loss by diet control and exercise proved most effective for adult males with severe or moderate OSA [65].

OTHER TREATMENTS

Some studies concerned that, in temporomandibular disorder patients with OSA, the mandibular advancement device may exacerbate their temporomandibular disorder symptoms. However, a meta-analysis on the topic found that use of the device did not severely exacerbate the patients’ symptoms [66].

Various devices have been developed that change the sleeping positions of patients with severe OSA in the supine position, and numerous studies have been performed on the devices. A meta-analysis found that some of these devices were partially effective, but not as effective as CPAP [67].

Nasal congestion has significant effect on compliance with CPAP. It has been expected that the nasal steroid spray may improve CPAP compliance or increase the time of its use by reducing nasal congestion in OSA patients. A meta-analysis on this issue concluded that nasal steroid spray increased the time of a single CPAP use by 0.4 hour on average, not statistically significant due to the small sample size [68].

OTHER FINDINGS

Alcohol, caffeine, and tobacco have been suspected of exacerbating OSA symptoms. According to a meta-analysis on this issue, alcohol consumption increases OSA occurrence by 1.33 times (95% CI: 1.10–1.62), whereas smoking was not associated with OSA. There was no sufficient data to verify the association between caffeine and OSA [69].

A meta-analysis was performed with 21 studies (54,276 patients) on the effect of OSA on the prognosis of COVID-19 patients. OSA proved to be a seriously negative prognostic factor, as it increased the progress of severe COVID-19 by 1.70 times (95% CI: 1.18–2.45), admission to intensive care units (ICUs) by 1.76 times (95% CI: 1.51–2.05), use of ventilators by 1.67 times (95% CI: 1.48–1.88), and mortality by 1.74 times (95% CI: 1.39–2.19) [70].

Some studies demonstrated that OSA patient have olfactory dysfunction. A meta-analysis on these studies found that threshold, discrimination, identification (TDI) score of OSA patients (24.3±5.6) was lower than that of the control group (30.7±6.0). The AHI was inversely correlated with the TDI score. However, the correlation was minimal [71].

It has been also reported that OSA patients are more likely to be involved in workplace accidents due to daytime sleepiness. A meta-analysis on this issue reported a 1.64 time increase in workplace accidents in OSA patients comparing with the control group (95% CI: 1.24–2.16), and a 1.68 times increase in accidents involving professional drivers with OSA (95% CI: 1.14–2.49) [72].

The telomere is a region of repetitive nucleotide sequences at the end of the chromosome. Telomere shortens each time a cell divides that is associated with the aging of the cells. According to a meta-analysis study on the relationship between OSA and the length of the telomere, the telomere of OSA patients was shorter than that of the control group, and the gap increased in older patients. As such, the authors emphasized the importance of early treatment for OSA [73].

A meta-analysis on the association between OSA and pregnancy-related diseases found that the OSA increases gestational hypertension by 1.97 times, gestational diabetes by 1.55 times, pre-eclampsia by 2.35 times, the frequency of Cesarean section operation by 1.42 times, post-operation wound infection by 1.87 times, pulmonary edema by 6.35 times, preterm birth by 1.62 times, and ICU admission of newborns by 1.28 times [74].

CONCLUSIONS

OSA auses various diseases including cancer and the previously known complications such as cardiovascular diseases and neurological-cognitive disorders. While CPAP is widely known as the most effective treatment, studies have demonstrated its limitations in preventing cardiovascular diseases, diabetes, and other complications. The soft palate surgery has clear benefits, and hypoglossal nerve stimulation, various medications, and exercise improve the effects of OSA treatment.

Notes

Ethics Statement

Ethical approval and informed consents does not apply to this article.

Availability of Data and Material

All data generated or analyzed during the study are included in this published article.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Jae Hoon Cho. Data curation: Jae Hoon Cho. Formal analysis: Jae Hoon Cho. Funding acquisition: Jae Hoon Cho. Investigation: all authors. Methodology: all authors. Project administration: Jae Hoon Cho. Resources: Jin Kook Kim, Jae Hoon Cho. Software: Jae Hoon Cho. Supervision: Jae Hoon Cho. Validation: all authors. Visualization: Jae Hoon Cho. Writing—original draft: Bo Yoon Choi, Jae Hoon Cho. Writing—review & editing: all authors.

Funding Statement

None

References

1. Di Fusco SA, Pignalberi C, Santini L, Colivicchi F, Santini M. Arrhythmias and sleep apnea: physiopathologic link and clinical implications. J Interv Card Electrophysiol 2020;57(3):387–97.

2. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019;7(8):687–98.

3. Maspero C, Giannini L, Galbiati G, Rosso G, Farronato G. Obstructive sleep apnea syndrome: a literature review. Minerva Stomatol 2015;64(2):97–109.

4. Marin JM, Agusti A, Villar I, Forner M, Nieto D, Carrizo SJ, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012;307(20):2169–76.

5. Marshall NS, Wong KK, Phillips CL, Liu PY, Knuiman MW, Grunstein RR. Is sleep apnea an independent risk factor for prevalent and incident diabetes in the Busselton Health Study? J Clin Sleep Med 2009;5(1):15–20.

6. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353(19):2034–41.

7. Patel N, Donahue C, Shenoy A, Patel A, El-Sherif N. Obstructive sleep apnea and arrhythmia: a systemic review. Int J Cardiol 2017;228:967–70.

8. Cho JH. Theory and practice of meta-analysis. J Rhinol 2020;27(2):83–9.

9. Dong JY, Zhang YH, Qin LQ. Obstructive sleep apnea and cardiovascular risk: meta-analysis of prospective cohort studies. Atherosclerosis 2013;229(2):489–95.

10. Loke YK, Brown JW, Kwok CS, Niruban A, Myint PK. Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2012;5(5):720–8.

11. Xie C, Zhu R, Tian Y, Wang K. Association of obstructive sleep apnoea with the risk of vascular outcomes and all-cause mortality: a meta-analysis. BMJ Open 2017;7(12)e013983.

12. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004;110(4):364–7.

13. Strausz S, Havulinna AS, Tuomi T, Bachour A, Groop L, Mäkitie A, et al. Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a longitudinal population-based study in Finland. BMJ Open 2018;8(10)e022752.

14. Zhou X, Liu F, Zhang W, Wang G, Guo D, Fu W, et al. Obstructive sleep apnea and risk of aortic dissection: a meta-analysis of observational studies. Vascular 2018;26(5):515–23.

15. Cuspidi C, Tadic M, Sala C, Gherbesi E, Grassi G, Mancia G. Obstructive sleep apnoea syndrome and left ventricular hypertrophy: a meta-analysis of echocardiographic studies. J Hypertens 2020;38(9):1640–9.

16. Zeng J, Wei M, Li T, Chen W, Feng Y, Shi R, et al. Risk of obstructive sleep apnea in Parkinson’s disease: a meta-analysis. PLoS One 2013;8(12)e82091.

17. Aloia MS, Arnedt JT, Smith L, Skrekas J, Stanchina M, Millman RP. Examining the construct of depression in obstructive sleep apnea syndrome. Sleep Med 2005;6(2):115–21.

18. Asghari A, Mohammadi F, Kamrava SK, Tavakoli S, Farhadi M. Severity of depression and anxiety in obstructive sleep apnea syndrome. Eur Arch Otorhinolaryngol 2012;269(12):2549–53.

19. Krell SB, Kapur VK. Insomnia complaints in patients evaluated for obstructive sleep apnea. Sleep Breath 2005;9(3):104–10.

20. Vaughn BV, D’Cruz OF. Obstructive sleep apnea in epilepsy. Clin Chest Med 2003;24(2):239–48.

21. Nagayoshi M, Punjabi NM, Selvin E, Pankow JS, Shahar E, Iso H, et al. Obstructive sleep apnea and incident type 2 diabetes. Sleep Med 2016;25:156–61.

22. Gu X, Luo X, Wang X, Tang J, Yang W, Cai Z. The correlation between obstructive sleep apnea and diabetic neuropathy: a meta-analysis. Prim Care Diabetes 2018;12(5):460–6.

23. Liu T, Zhan Y, Wang Y, Li Q, Mao H. Obstructive sleep apnea syndrome and risk of renal impairment: a systematic review and metaanalysis with trial sequential analysis. Sleep Breath 2021;25(1):17–27.

24. Zhou J, Xia S, Li T, Liu R. Association between obstructive sleep apnea syndrome and nocturia: a meta-analysis. Sleep Breath 2020;24(4):1293–8.

25. Kellesarian SV, Malignaggi VR, Feng C, Javed F. Association between obstructive sleep apnea and erectile dysfunction: a systematic review and meta-analysis. Int J Impot Res 2018;30(3):129–40.

26. Lippi G, Mattiuzzi C, Franchini M. Sleep apnea and venous thromboembolism. A systematic review. Thromb Haemost 2015;114(5):958–63.

27. Wu ZH, Yang XP, Niu X, Xiao XY, Chen X. The relationship between obstructive sleep apnea hypopnea syndrome and gastroesophageal reflux disease: a meta-analysis. Sleep Breath 2019;23(2):389–97.

28. Shi T, Min M, Sun C, Cheng C, Zhang Y, Liang M, et al. A meta-analysis of the association between gout, serum uric acid level, and obstructive sleep apnea. Sleep Breath 2019;23(4):1047–57.

29. Wali S, Mustafa M, Manzar D, Bawazir Y, Attar S, Fathaldin O, et al. Prevalence of obstructive sleep apnea in patients with rheumatoid arthritis. J Clin Sleep Med 2020;16(2):259–65.

30. Pihtili A, Bingol Z, Kiyan E, Cuhadaroglu C, Issever H, Gulbaran Z. Obstructive sleep apnea is common in patients with interstitial lung disease. Sleep Breath 2013;17(4):1281–8.

31. Wu CY, Riangwiwat T, Rattanawong P, Nesmith BLW, Deobhakta A. Association of obstructive sleep apnea with central serous chorioretinopathy and choroidal thickness: a systematic review and metaanalysis. Retina 2018;38(9):1642–51.

32. Sedky K, Gaisl T, Bennett DS. Prevalence of obstructive sleep apnea in joint hypermobility syndrome: a systematic review and meta-analysis. J Clin Sleep Med 2019;15(2):293–9.

33. Cheng L, Guo H, Zhang Z, Yao Y, Yao Q. Obstructive sleep apnea and incidence of malignant tumors: a meta-analysis. Sleep Med 2021;84:195–204.

34. Tan NKW, Yap DWT, Tan BKJ, Teo YH, Tan EKH, Chan JY, et al. The association of obstructive sleep apnea with melanoma incidence and mortality: a meta-analysis of 5,276,451 patients. Sleep Med 2021;88:213–20.

35. Shang W, Zhang Y, Liu L, Chen F, Wang G, Han D. Benefits of continuous positive airway pressure on blood pressure in patients with hypertension and obstructive sleep apnea: a meta-analysis. Hypertens Res 2022;45(11):1802–13.

36. Labarca G, Dreyse J, Drake L, Jorquera J, Barbe F. Efficacy of continuous positive airway pressure (CPAP) in the prevention of cardiovascular events in patients with obstructive sleep apnea: systematic review and meta-analysis. Sleep Med Rev 2020;52:101312.

37. Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, et al. Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: a systematic review and metaanalysis. JAMA 2017;318(2):156–66.

38. Labarca G, Reyes T, Jorquera J, Dreyse J, Drake L. CPAP in patients with obstructive sleep apnea and type 2 diabetes mellitus: systematic review and meta-analysis. Clin Respir J 2018;12(8):2361–8.

39. Chen Q, Lin G, Chen Y, Wu C, Li C, Huang J, et al. Impact of CPAP treatment for obstructive sleep apnea on visceral adipose tissue: a meta-analysis of randomized controlled trials. Sleep Breath 2021;25(2):555–62.

40. Tian Z, Xiao J, Kang J, Sun H, Mu Z, Tong D, et al. Effects of continuous positive airway pressure on cell adhesion molecules in patients with obstructive sleep apnea: a meta-analysis. Lung 2021;199(6):639–51.

41. Ken-Dror G, Fry CH, Murray P, Fluck D, Han TS. Changes in cortisol levels by continuous positive airway pressure in patients with obstructive sleep apnoea: meta-analysis of 637 individuals. Clin Endocrinol (Oxf) 2021;95(6):909–17.

42. Chen R, Huang ZW, Lin XF, Lin JF, Yang MJ. Effect of continuous positive airway pressure on albuminuria in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 2022;26(1):279–85.

43. Li C, Wu ZH, Pan XL, Yuan K. Effect of continuous positive airway pressure on gastroesophageal reflux in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 2021;25(3):1203–10.

44. Yang Z, Du G, Ma L, Lv Y, Zhao Y, Yau TO. Continuous positive airway pressure therapy in obstructive sleep apnoea patients with erectile dysfunction—a meta-analysis. Clin Respir J 2021;15(2):163–8.

45. Samutsakorn P, Hirunwiwatkul P, Chaitusaney B, Charakorn N. Lingual tonsillectomy with palatal surgery for the treatment of obstructive sleep apnea in adults: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2018;275(4):1005–13.

46. Kotecha BT, Hall AC. Role of surgery in adult obstructive sleep apnoea. Sleep Med Rev 2014;18(5):405–13.

47. Sheen D, Abdulateef S. Uvulopalatopharyngoplasty. Oral Maxillofac Surg Clin North Am 2021;33(2):295–303.

48. Enoz M. Limitation of the palatal surgery in OSA patients. Sleep Med 2006;7(1):89–90.

49. Pang KP, Plaza G, Baptista J PM, O’Connor Reina C, Chan YH, Pang KA, et al. Palate surgery for obstructive sleep apnea: a 17-year metaanalysis. Eur Arch Otorhinolaryngol 2018;275(7):1697–707.

50. Lechien JR, Chiesa-Estomba CM, Fakhry N, Saussez S, Badr I, Ayad T, et al. Surgical, clinical, and functional outcomes of transoral robotic surgery used in sleep surgery for obstructive sleep apnea syndrome: a systematic review and meta-analysis. Head Neck 2021;43(7):2216–39.

51. Ratneswaran D, Guni A, Pengo MF, Al-Sherif M, He B, Cheng MC, et al. Electrical stimulation as a therapeutic approach in obstructive sleep apnea—a meta-analysis. Sleep Breath 2021;25(1):207–18.

52. Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 2003;26(5):252–7.

53. Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med 2015;16(1):9–18.

54. Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2018;366(2):367–76.

55. Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep 2016;39(7):1379–87.

56. Wang J, Yang S, Li X, Wang T, Xu Z, Xu X, et al. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials. Sleep Med 2021;79:40–7.

57. Wang J, Li X, Yang S, Wang T, Xu Z, Xu J, et al. Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a meta-analysis from randomized controlled trials. Pharmacol Res 2021;167:105522.

58. Messineo L, Eckert DJ, Lim R, Chiang A, Azarbarzin A, Carter SG, et al. Zolpidem increases sleep efficiency and the respiratory arousal threshold without changing sleep apnoea severity and pharyngeal muscle activity. J Physiol 2020;598(20):4681–92.

59. Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther 2016;38(11):2340–72.

60. Wang D, Tang Y, Chen Y, Zhang S, Ma D, Luo Y, et al. The effect of non-benzodiazepine sedative hypnotics on CPAP adherence in patients with OSA: a systematic review and meta-analysis. Sleep 2021;44(8):zsab077.

61. Neuzeret PC, Sakai K, Gormand F, Petitjean T, Buda C, Sastre JP, et al. Application of histamine or serotonin to the hypoglossal nucleus increases genioglossus muscle activity across the wake-sleep cycle. J Sleep Res 2009;18(1):113–21.

62. Kubin L, Tojima H, Davies RO, Pack AI. Serotonergic excitatory drive to hypoglossal motoneurons in the decerebrate cat. Neurosci Lett 1992;139(2):243–8.

63. AbdelFattah MR, Jung SW, Greenspan MA, Padilla M, Enciso R. Efficacy of antidepressants in the treatment of obstructive sleep apnea compared to placebo. A systematic review with meta-analyses. Sleep Breath 2020;24(2):443–53.

64. Lins-Filho O, Porto Aguiar JL, Vieira de Almeida JR, Soares AH, Ritti-Dias R, Julia da Silva M, et al. Effect of exercise training on body composition in patients with obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med 2021;87:105–13.

65. Carneiro-Barrera A, Díaz-Román A, Guillén-Riquelme A, Buela-Casal G. Weight loss and lifestyle interventions for obstructive sleep apnoea in adults: systematic review and meta-analysis. Obes Rev 2019;20(5):750–62.

66. Alessandri-Bonetti A, Bortolotti F, Moreno-Hay I, Michelotti A, Cordaro M, Alessandri-Bonetti G, et al. Effects of mandibular advancement device for obstructive sleep apnea on temporomandibular disorders: a systematic review and meta-analysis. Sleep Med Rev 2019;48:101211.

67. Barnes H, Edwards BA, Joosten SA, Naughton MT, Hamilton GS, Dabscheck E. Positional modification techniques for supine obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med Rev 2017;36:107–15.

68. Charakorn N, Hirunwiwatkul P, Chirakalwasan N, Chaitusaney B, Prakassajjatham M. The effects of topical nasal steroids on continuous positive airway pressure compliance in patients with obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath 2017;21(1):3–8.

69. Taveira KVM, Kuntze MM, Berretta F, de Souza BDM, Godolfim LR, Demathe T, et al. Association between obstructive sleep apnea and alcohol, caffeine and tobacco: a meta-analysis. J Oral Rehabil 2018;45(11):890–902.

70. Hariyanto TI, Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Sleep Med 2021;82:47–53.

71. Iannella G, Magliulo G, Maniaci A, Meccariello G, Cocuzza S, Cammaroto G, et al. Olfactory function in patients with obstructive sleep apnea: a meta-analysis study. Eur Arch Otorhinolaryngol 2021;278(3):883–91.

72. Chou KT, Tsai YL, Yeh WY, Chen YM, Huang N, Cheng HM. Risk of work-related injury in workers with obstructive sleep apnea: a systematic review and meta-analysis. J Sleep Res 2022;31(1)e13446.

73. Huang P, Zhou J, Chen S, Zou C, Zhao X, Li J. The association between obstructive sleep apnea and shortened telomere length: a systematic review and meta-analysis. Sleep Med 2018;48:107–12.

74. Liu L, Su G, Wang S, Zhu B. The prevalence of obstructive sleep apnea and its association with pregnancy-related health outcomes: a systematic review and meta-analysis. Sleep Breath 2019;23(2):399–412.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.